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Summary
The activation of hepatitis B virus (HBV)-related hepatitis is associated with both natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). We analyzed the association between the immune response and changes in the proportion of Pre-S deletion variants. We quantified Pre-S deleted HBV (HBV-del) and wild-type HBV (HBV-wt) DNA levels in sera obtained from HBV-infected mice and chronic hepatitis B patients. In chronic hepatitis B patients, the HBV-del proportion usually increased during or after ALT elevation but did not occur during all ALT elevations. To clarify this difference in the immunological responses, we performed in vivo analyses using HBV-infected human hepatocyte chimeric mice. Although HBV-del proportions did not change in mice with NK cell-associated hepatitis or in mice treated with entecavir, the proportions sharply increased in mice with CTL-associated hepatitis. Furthermore, the number of patients in which HBV-del proportions were greater than 5% was significantly higher in chronic hepatitis B patients than in asymptomatic carriers (P = 0.023). We identified associations between virological response in chronic hepatitis B patients and two different immune responses. The proportion of HBV-del
| INTRODUC TI ON
Hepatitis B virus (HBV) is a member of the Hepadnaviridae, a family of small hepatotropic DNA viruses characterized by infection specificity to their respective animal hosts. [1] [2] [3] Repetitive activation of hepatitis occurs during chronic HBV infection of human hepatocytes, driving one of the most important causes of liver disease progression. However, the mechanism of hepatitis activation has not been sufficiently clarified, and it is difficult to predict hepatitis inactivation after alanine aminotransferase (ALT) elevation in the clinical course. Previous reports have identified several HBV DNA deletion variants in the PreS/S region of the HBV genome in the sera of chronic hepatitis B patients or in HBV-infected livers, and the presence of deletion variants has been shown to be associated with the clinical status of chronic hepatitis B, the immune response to interferon treatment, or with HBV replication. [4] [5] [6] However, the association between the presence of HBV deletion variants and activation of hepatitis has not been fully clarified.
Hepatitis B virus can transiently infect only a limited range of closely related mammals, including chimpanzees and tree shrews, and small animals such as mice and rats cannot be infected. Until recently, this strong host specificity has made it difficult to establish a small animal model to study the mechanism of HBV infection and replication in vivo. The human hepatocyte chimeric mouse model, in which the hepatocytes of immunocompromised mice are largely replaced by transplanted human hepatocytes, was developed as a small animal model of HBV infection and replication. 7, 8 Using this chimeric mouse model, it is possible to evaluate sensitivity to nucleos(t)ide analogues (NAs) using HBV clones containing drug resistant mutations. Furthermore, we demonstrated that the different virological responses might be associated with ALT normalization after HBV exacerbation in chronic hepatitis B patients. Kawasaki, Japan). All transplanted human hepatocytes shared the HLA-A24 antigen. Infection, extraction of serum samples and euthanasia were performed under ether anaesthesia. The concentration of human serum albumin, which is correlated with the repopulation index, was measured as described previously. 8, 14 The experiments were performed in accordance with the guidelines of the local committee for animal experiments at Hiroshima University (Approval ID:
| MATERIAL S AND ME THODS

| Human serum samples for HBV infection
| Human hepatocyte chimeric mice experiments
27-113-6 and A17-106).
Peripheral blood mononuclear cells were isolated using FicollHypaque density gradient centrifugation from three healthy, variants could be a useful biomarker for distinguishing between chronic hepatitis and asymptomatic carriers.
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Highlights
• We found different influences on the proportion of Pre-S deletion variants by natural killer (NK) cell-associated and cytotoxic T lymphocyte (CTL)-associated immune responses using an HBV-infected human hepatocyte chimeric mouse model.
• Using clinical samples, we also found that the proportion of Pre-S deleted HBV was significantly higher in chronic hepatitis B patients than in asymptomatic carriers.
• We conclude that the proportion of Pre-S deletion variants could be a useful biomarker for distinguishing between chronic hepatitis patients and asymptomatic carriers.
unvaccinated blood donors and one chronic hepatitis B patient with HLA-A24 antigen who recovered from an episode of severe acute hepatitis B. The details of the donors and inoculation methods were described previously. 
| Patients in the clinical study
Fifty-nine Japanese patients with chronic HBV genotype C infection were enrolled in this study. None of the patients had ever been treated with antiviral agents. Sera were collected from 2001 to 2016
at Hiroshima University Hospital and stored at −80°C until use. None of the patients were infected with other viruses, such as human immunodeficiency virus or hepatitis C virus, nor had evidence of other liver diseases, such as autoimmune hepatitis or alcoholic liver disease.
To avoid the confounding effects of alcoholic liver dysfunction, patients with total ethanol intake of more than 100 kg were excluded.
15
All patients gave written informed consent to participate in this study.
The experimental protocol conformed to the ethical guidelines of the
Declaration of Helsinki and was approved by the Hiroshima University
Hospital ethical committee (Approved ID: E726).
| Analysis of HBV markers
Quantification of serum HBsAg was performed with ARCHITECT HBsAg (Abbott, Tokyo, Japan). High HBsAg titre was measured with 4000-fold diluted serum. The quantitative range of HBsAg was 0.05-1 000 000 IU/mL. HBeAg was also analyzed by ARCHITECT HBsAg (Abbott Japan, Tokyo, Japan). Serum HBV DNA was quantified by real-time polymerase chain reaction (PCR) (Abbott Japan, Tokyo, Japan). The lower quantitation limit of this assay is 2.1 log copies/mL.
| Statistical analysis
Differences among groups were examined for statistical significance using the Mann-Whitney U and Chi-squared tests. All statistical analyses were performed using SPSS ® ver. 19.0 (SPSS Inc., Chicago, IL). P values less than 0.05 were considered to be statistically significant.
| RE SULTS
| Identification of deletions in the HBV Pre-S region
To evaluate the presence of deletions in the Pre-S region of the HBV genome in chronic hepatitis B patients, we extracted DNA from sera from patients with chronic hepatitis and amplified full-length HBV DNA using primers designed to amplify the complete genome. After amplification, we performed electrophoresis and found a PCR product that was shorter than the expected full-length HBV DNA. To verify that the shorter PCR product was amplified from HBV DNA,
we performed direct sequencing analysis and identified a deletion in the Pre-S region (deletion: nt3016-nt3198) ( Figure 1A ). As the same deletion was observed in sera from many chronic hepatitis B patients, we analyzed the association between the presence of this Pre-S deleted HBV (HBV-del) mutant and clinical features in patients.
| Quantification of pre-S deleted HBV mutants
To establish a system to quantify HBV-del mutants, we designed new specific primer sets that can amplify only HBV-del or that can amplify both wild-type HBV (HBV-wt) and HBV-del ( Figure 1B ). To verify the specificity of the designed primers, we amplified the mixtures of HBV-wt and/or HBV-del expression plasmids mixed in several proportions. When we used Pre-S deletion primer sets, HBV-del was specifically amplified without amplifying HBV-wt ( Figure 1C ).
Conversely, both wild type and HBV-del could be amplified using the surrounding Pre-S deletion primer set ( Figure 1D ). To verify the specificity of Pre-S deletion primer set, real-time PCR was performed using mixtures with several concentrations of HBV-wt and HBV-del expression plasmids. Both HBV-wt and HBV-del DNA could be amplified with HBV full primers, and the HBV DNA titres were similar among all mixtures ( Figure 1E ). Only HBV-del DNA could be specifically amplified with the Pre-S deletion primer set ( Figure 1F ). Based on these results, we consider this method to be useful for comparing the relative amounts of HBV-wt and HBV-del by real-time PCR.
| Change in the proportion of Pre-S deleted HBV in chronic hepatitis B patients
To analyze the association between HBV-del and the clinical course in patients, we measured the amounts of HBV-wt and HBV-del and examined ALT level with respect to the proportion of HBV-del. Four representative cases, in which the proportion of HBV-del could be monitored for more than 3 years, are described below.
| Case 1
A 32-year-old man had been diagnosed with HBeAg-positive chronic hepatitis B (HBV genotype C). At 1 year after the first visit, he had been treated with 500 IU of interferon-α 3 times per week for 6 months, and by 1 year after interferon treatment, his ALT levels had gradually decreased. However, 3 years after the first visit, an ALT flare occurred, but his ALT level rapidly decreased without antiviral therapy. Although the rate of HBV-del increased transiently during the ALT flare, the rate subsequently recovered to levels similar to that before the ALT flare (Figure 2A ). After the ALT flare, HBe seroconversion occurred, and ALT level and the proportion of HBV-del remained steady for 2 years after the ALT flare.
| Case 2
A 26-year-old man had been diagnosed with HBeAg-negative chronic hepatitis B (HBV genotype C). He was followed up without antiviral therapy for 7 years after the first visit. During the follow-up period, ALT flares occurred 6 times. We measured the proportion of HBVdel and compared changes in the proportion of HBV-del with respect to ALT elevation. The proportions of HBV-del increased along with each ALT flare except one ( Figure 2B ). After the 6th ALT flare, entecavir treatment was started, and HBV DNA was reduced to undetectable levels and ALT decreased to within the normal range.
| Case 3
A 32-year-old woman had been diagnosed with HBeAg-negative chronic hepatitis B (HBV genotype C), and she had been treated with PEG-IFN-α2a for 3 years prior to the first visit. ALT flare occurred F I G U R E 1 Identification and quantification of an HBV Pre-S deletion variant. A, DNA was extracted from sera of chronic hepatitis B patients and amplified using a primer set designed to amplify the full HBV genome. PCR products shorter than the expected full-length HBV DNA were purified, and direct sequencing was performed. A 183 nt deletion in the Pre-S region (nt3016-nt3198) was observed in several patients. B, The orientation of the primers is shown. The forward primer for amplifying HBV-del was designed to straddle the deletion. C,D, Solutions containing various concentrations of full-length genomic HBV and Pre-S deleted HBV expression plasmids were amplified using Pre-S deletion primers and surrounding Pre-S deletion primer sets, respectively. E,F, To verify the specificities of primer sets by real time PCR, mixtures with several concentrations of HBV-wt and HBV-del expression plasmids were amplified using HBV full primer and the Pre-S deletion primer set, respectively.
twice within 3 years after the first visit, and an increase in the proportion of HBV-del was observed with each ALT flare. However, following the flares, the proportion of HBV-del rapidly decreased to pre-flare levels ( Figure 2C ).
| Case 4
A 30-year-old man had been diagnosed with HBeAg-positive chronic hepatitis B (HBV genotype C). Although his HBV DNA level was high F I G U R E 1 Continued (more than 10 Log copies/ml), his ALT remained steady for 3 years.
During this period, the proportion of HBV-del did not change significantly ( Figure 2D ). An ALT flare occurred 3 years after the first visit, but we could not observe an increase in the proportion of HBV-del.
We observed two different patterns in the proportion of HBVdel in response to ALT flare in these patients. To clarify these differences, we analyzed the proportion of HBV-del using the HBVinfected human chimeric mouse model.
| Confirmation of the association between the changes of proportions of HBV-del and ALT flare in vivo
In our previous studies, we identified two different immune reactions (CTL-mediated and NK-cell mediated hepatitis) that may occur in the severe hepatitis B mouse model. To examine the different immune reactions at the time of ALT flare, changes in the proportions of HBV-del were analyzed using several different mouse models. In an HBV-infected mouse model without antiviral treatment, the proportion of HBV-del remained unchanged ( Figure 3A) . However, in mice in which severe CTL-mediated hepatitis was induced by injecting human PBMCs, the amount of full-length HBV decreased relative to that of HBV-del ( Figure 3B ).
Conversely, in mice with severe NK-cell-mediated hepatitis, levels of both full-length HBV and HBV-del decreased together, and the proportion of HBV-del did not significantly change during and after severe hepatitis ( Figure 3C ). To verify whether the changes in the proportions of HBV-del were CTL-specific reactions, we also analyzed the proportions using chimeric mice treated with entecavir for HBV DNA reduction. As shown in Figure 3D , levels of both full-length HBV and HBV-del decreased together, and the proportion of HBV-del remained steady during entecavir treatment.
Therefore, the increase in the proportion of HBV-del was induced as a CTL-mediated immune response. 
| Analyze the association of clinical features and the proportions of HBV-del
To analyze the association between clinical features and the proportion of HBV-del, 59 chronic HBV-infected patients were enrolled (Table 1) , and the proportion of HBV-del was measured using patient sera before starting antiviral therapy. Fourteen patients (23.7%) carried HBV-del at a proportion greater than 5%, and 5 patients (8.5%)
carried HBV-del with a proportion greater than 10% (Figure 4 ). There was no difference in the proportions of HBV-del between HBeAgpositive and -negative HBV carriers, and there was no correlation between the proportions of HBV-del and HBV-wt DNA levels.
Comparing the proportion of HBV-del between asymptomatic carriers and chronic hepatitis B patients, there was no symptomatic carrier whose proportion of HBV-del was more than 5% (Figure 4 ), and the frequency of patients who carried >5% HBV-del in chronic hepatitis patients was significantly higher than in asymptomatic carriers (P = 0.023) ( Table 1) . Therefore, we considered that presence of a higher proportion (≥5%) of HBV-del might be a biomarker to discriminate asymptomatic carriers from HBV carriers whose ALT levels were less than 30U/L.
| D ISCUSS I ON
Hepatitis B virus variants with deletions in the Pre-S region are often observed in chronic hepatitis B patients. Although variation in the lengths of the Pre-S deletions has been reported, most deletions have been identified in the Pre-S1 and Pre-S2 regions. [16] [17] [18] [19] [20] In the present study, HBV clones with Pre-S deletions were observed in 28.8% (17/59) of chronic HBV carriers, with the deletion at nt3016-nt3198 the most frequent ( Figure 1 ). To quantify HBV-del clones, we constructed novel primer sets and compared the proportion of HBV-del in chronic hepatitis B patients. We constructed HBV expression plasmids containing full genomic HBV DNA or Pre-S deleted HBV (nt3016-nt3198 deletion) and performed PCR to verifying the quality of the primers. As PCR products amplified from full genomic HBV plasmid could not be observed using the Pre-S deletion-specific primers ( Figure 1C ), we considered F I G U R E 3 Changes in the proportion of Pre-S deletion variants in HBV-infected chimeric mice. Changes in the frequency of HBV-del was analyzed using the HBV-infected human hepatocyte chimeric mouse model. A, The proportion of HBV-del remained unchanged in an HBVinfected mouse model without PBMC injection or antiviral treatment. B, The proportion of HBV-del increased as the amount of full-length HBV decreased in mice with severe CTL-mediated hepatitis. C, The proportion of HBV-del remained steady in mice with severe NK-cell mediated hepatitis. D, The proportion of HBV-del remained steady in mice treated with entecavir that the Pre-S deletion primer set could amplify HBV-del specifically and that the primer sets could be useful for quantification of HBV-del.
Subsequently, we quantified both full genomic and HBV-del using chronic hepatitis B patient sera and analyzed changes in the proportion of HBV-del. As shown in Figure 2 , the proportion of HBVdel clones increased to more than 10% after ALT flares. However, at several ALT elevations, we failed to observe this increase ( Figure 2B and D). Furthermore, ALT elevations both with and without corresponding increases in proportion or HBV-del could be observed in the same patient ( Figure 2B ). Based on these results, we concluded that ALT elevations with and without increases in the proportion of HBV-del could be induced via two different immune responses.
We recently generated a new fulminant hepatitis B mouse model using human hepatocyte chimeric mice. 12, 13 In HBV-infected human hepatocyte chimeric mice derived from uPA/SCID mice or cDNA-uPA/SCID mice, fulminant hepatitis was induced by NK cells after human PBMC injection. In this mouse model, Fas expression in human hepatocytes of mouse livers was up-regulated by HBV infection, and NK cells were activated via Fas/FasL signalling. 12 As shown in Figure 3C , both full genomic HBV and HBV-del decreased in parallel during fulminant hepatitis, and, therefore, the proportion of HBV-del did not change significantly. On the other hand, in HBV-infected chimeric mice derived from TK-NOG mice, fulminant hepatitis was induced by HBV-specific CTLs, and the amount of full-length genomic HBV was reduced more strongly than HBVdel; therefore, the proportion of HBV-del increased in these mice ( Figure 3B ). As changes in the proportion of HBV-del were not observed and fulminant hepatitis was not induced as well as in mice that were not treated with entecavir ( Figure 3A and D) , increases in the proportion of HBV-del may represent a specific response to the activation of CTLs. Although several target epitopes to HBVspecific CTLs have been identified in the Pre-S and core regions, [21] [22] [23] [24] [25] [26] [27] [28] [29] and HBV-specific CTLs are considered to kill full genomic HBV particles, [30] [31] [32] [33] a strong association between the presence of Pre-S deletion and CTL-derived hepatitis was indicated in the present study.
Therefore, we conclude that CTLs might become activated by recognizing epitopes in the Pre-S region and inducing hepatitis.
Finally, to analyze clinical features, we also analyzed the association between clinical factors and the proportion of HBV-del.
However, we could not find associations between the proportion of HBV-del and HBeAg presence, HBV DNA levels, or platelet counts (data not shown). On the other hand, the number of patients whose proportion of HBV-del were more than 5% in chronic hepatitis B patients was significantly higher than in asymptomatic carriers ( Figure 4 and Table 1 ). As the increase in the proportion of HBV-del was considered to be associated with ALT elevation via CTL activation, we consider that increases in the proportion of HBV-del could not be 
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